Sign in Subscribe
Pharmaceutical industry

Steroid Stocks: A Critical Analysis of Generex Biotechnology, US Natural Gas Corp, and Anavex Life Sciences

Strategic Insights

— 1 min read

Generex Biotechnology Corp., US Natural Gas Corp., and Anavex Life Sciences Corp. have been identified by SteroidStocks.com as companies on the verge of significant growth. These three publicly traded companies have been featured in the M2 PressWIRE report, highlighting their potential for expansion and success. However, a closer examination of their financials and industry trends reveals a more nuanced picture.

Key Takeaways:

  • Generex Biotechnology Corp. (GNBT) has faced significant challenges in its recent financial performance, with a net loss of $14.6 million in the first half of 2010. The company's flagship product, buccal insulin, is still in Phase III clinical trials and has yet to gain FDA approval.
  • US Natural Gas Corp. (UNGS) has seen a decline in its stock price over the past year, from $0.40 to $0.12, despite its efforts to increase production through the completion of several wells.
  • Anavex Life Sciences Corp. (AVXL) has gained significant traction in the industry with its novel drug candidate, ANAVEX 2-73, being prepared for Phase I clinical trials. The company's SIGMACEPTOR(TM) Discovery Platform has shown promise in the treatment of neurological and cancer diseases.
  • Generex Biotechnology Corp. has a significant capital deficit, with a total debt of $13.3 million as of June 30, 2010.
  • US Natural Gas Corp.'s recent installation of a Sulfa Treatment facility in West Virginia is an attempt to improve its natural gas production and profitability.
  • Anavex Life Sciences Corp. has partnered with Genesis BioPharma Group and ABX-CRO Advanced Pharmaceutical Services to advance its lead compound, ANAVEX 2-73.

Statistics:

  • Generex Biotechnology Corp. had a 1H 2010 revenue of $4.5 million, down 20% from 1H 2009.
  • US Natural Gas Corp. has a total proved reserves of 197 million cubic feet as of December 31, 2009.
  • Anavex Life Sciences Corp. has completed pre-clinical studies, including oral and IV dosing, and 28-day animal toxicity studies.

Sources:

  • [Source 1] M2 PressWIRE - 11 August 2010
  • [Source 2] Generex Biotechnology Corp. - www.generex.com
  • [Source 3] US Natural Gas Corp. - www.usnatgascorp.com
  • [Source 4] Anavex Life Sciences Corp. - www.anavex.com
  • [Source 5] SteroidStocks.com - www.steroidstocks.com

Read more